Transplantation and Cellular Therapy Meetings

February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Carlos R. Bachier, MD, discusses the toxicity profile of lisocabtagene maraleucel that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.